Acorda Therapeutics crashes 40% after patients die in drug trial

  • Acorda Therapeutics, a drugmaker, plunged around 40% after patients died during the company’s Parkinson’s disease drug trial, according to Bloomberg’s Natasha Rausch.
  • Seven patients in the trial, which was in the final stages, developed a severe infection called sepsis, and five died.
  • The company said it would stop adding new patients to the trial.
  • It said it has no hypothesis yet for how the patients died, but four of the patients that developed sepsis also developed a condition called agranulocytosis, where white-blood cells disappear from the body, which can be linked to the drug.
  • Shares were up 50% for the year before the drop on Wednesday.
  • Read Bloomberg’s full story here.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at